ACRS Aclaris Therapeutics, Inc.

+0.41  (1.49%)
Previous Close 27.47
Open 27.51
Price To book 7.25
Market Cap 597.52M
Shares 21,432,000
Volume 121,548
Short Ratio 6.47
Av. Daily Volume 265,358

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met endpoints - November 15, 2016. NDA filing 1Q 2017.
Seborrheic keratosis (SK)
Phase 2 data released August 18, 2016. Endpoints met.
Common warts (verruca vulgaris)

Latest News

  1. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  2. Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
  3. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
  4. Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors
  5. Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick
  6. Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference
  7. Aclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up
  8. Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
  9. Why Aclaris (ACRS) Could Be Positioned for a Surge
  10. Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
  11. Coverage initiated on Aclaris Therapeutics by Leerink Partners
  12. Edited Transcript of ACRS earnings conference call or presentation 3-Nov-16 12:30pm GMT
  13. Aclaris Therapeutics, Inc. :ACRS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  14. Aclaris Files for Secondary Offering
  15. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St
  16. Pharma company targeting skin disorders plans $91M stock sale
  17. Why Aclaris Therapeutics, Inc. Stock Is Down Today
  18. Aclaris Announces Phase 3 Results, Will Submit NDA In Q1 2017
  19. ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition